Market Clinches 5-Day Bloodbath As Wall Street Yeet Chips to Hide in Medicine Cabinet…

"I was never really a chip guy anyway." - everyone who was, until Monday, a chip guy

By Friday's close, the only people still holding semiconductors with conviction were the ones who'd stopped opening their brokerage app. The Nasdaq booked its fifth straight losing session, slipping 0.24% to 25,297.62, as investors backed out of tech and mainlined anything that pays a dividend and doesn't depend on a robot going full Skynet.

That said, the thing that lit the fuse was none other than a New York Times report that OpenAI is mulling pushing its IPO to next year, spooked by SpaceX face-planting after its own debut and the case of the yips running through AI shares generally. Suddenly every chip name tied to the buildout got their cheeks clapped. Micron shed more than 6%, Intel dropped over 3%, and AMD gave back 2%, all on a story about a company that hasn't even filed yet living rent free in their shareholders' heads.

So why in da hell does OpenAI IPO delay matter to a memory-chip maker in Boise? Because the entire AI-infrastructure trade runs on the assumption that the money keeps coming. JPMorgan traders flagged worries about the "sustainability of their infrastructure spending given the delay in funding from the capital markets." Adam Crisafulli of Vital Knowledge put it even plainer: the delay "could slow the pace of infrastructure spending."

Translation: When the IPO that was supposed to refill the tank chickens out  reconsiders the timing of going public, everyone downstream of the spending starts soiling themselves. 

So you had a bad day? Well not as bad as Asia. SoftBank (read: OpenAI's single most enthusiastic backer) cratered more than 12% and dragged the whole region down with it. South Korea's Kospi got hit for 5.81% to 8,411.21 and the Kosdaq dropped 4.10%, because when the AI trade sneezes, the countries that actually build the chips catch the flu. Meaning, if you had a rough week, SoftBank is having a worse day than you.

Elsewhere, in the part of the market that was having a genuinely great day, the cash didn't leave so much as change outfits. It piled into healthcare for a second straight session, sending Eli Lilly up 7%, AbbVie up more than 4%, and Johnson & Johnson up almost 4%. Consumer staples tacked on nearly 1%, with financials and utilities also catching a bid.

Oh, and consumer sentiment came in better than expected and the inflation outlook improved, which on a normal day throws a party. The buzzkill arrived from Minneapolis Fed President Neel Kashkari, who now expects one rate hike will be needed this year as the Middle East conflict pushes prices higher. A market already riding the struggle bus does not love hearing the word "hike."

Which brings us to this: is it time to panic? Apparently no. Goldman Sachs’ John Flood is all “risk-on” as he said, "we're in buy dip mode," with every cohort of degens from retail to institutions shuffling their portfolios around. His read is that the week's wreckage is a sale, not a funeral.

Now of course, that alone doesn’t warrant a YOLO binge, but it’s something to take note of. Whether dip buyers actually show up Monday or just talk about it on a podcast remains to be seen. Regardless, this week was a bloodbath. Now it’s time to forget all about it (iykyk). Until next time, friends… 

If you read all of this, congrats for having a 10 second attention span (better than me). As always, here’s our heatmap for today.

 

 

☕ Market Gossip

> Trump eases pressure on Fed Chairman Kevin Warsh as inflation tops 4% (CNBC): Live look at Kevy Kev and Trump discussing interest rates… 

> Magnolia Oil & Gas Is in Lead to Acquire WildFire for Over $4 Billion (Bloomberg): Two words that shouldn’t mix… 

> Ex-Trump advisor John Bolton pleads guilty to retaining national defense information (CNBC): Straight to jail…  
 

“WTF” Meme of the Day

“Pre-IPO prices now on sale.” -per, Stock Chart

At the time of publishing, Stocks.News holds positions in Intel as mentioned in the article.